Functional_JJ and_CC Phenotypic_JJ Changes_NP in_IN Circulating_NP Lymphocytes_NP from_IN Hospitalized_JJ Zambian_JJ Children_NNS with_IN Measles_NP Measles_NP is_VBZ associated_VBN with_IN immunosuppression_NN and_CC increased_VBN susceptibility_NN to_TO secondary_JJ infections_NNS and_CC is_VBZ a_DT particular_JJ problem_NN in_IN developing_VBG countries_NNS ._SENT Lymphocyte_NN changes_NNS accompanying_VBG immune_JJ activation_NN and_CC regulation_NN of_IN the_DT immune_JJ response_NN may_MD contribute_VB to_TO immunosuppression_NN ._SENT To_TO evaluate_VB lymphocyte_NN changes_NNS during_IN measles_NN ,_, children_NNS (_( n_NN =_SYM 274_LS )_) hospitalized_VBN with_IN measles_NN in_IN Lusaka_NP ,_, Zambia_NP ,_, were_VBD evaluated_VBN at_IN entry_NN ,_, discharge_NN ,_, and_CC 1-month_JJ follow-up_NN and_CC compared_VBN to_TO healthy_JJ Zambian_JJ children_NNS (_( n_NN =_SYM 98_CD )_) ._SENT Lymphopenia_NP was_VBD present_JJ on_IN hospital_NN admission_NN and_CC reflected_VBD decreased_VBN CD4_NP and_CC CD8_NP T_NN cells_NNS but_CC resolved_VBN quickly_RB ._SENT Lymphopenia_NN was_VBD most_RBS marked_VBN in_IN girls_NNS ,_, in_IN those_DT with_IN temperatures_NNS of_IN >38.5C_NN ,_, and_CC in_IN malnourished_JJ children_NNS ._SENT CD4/CD8_NP ratios_NNS were_VBD decreased_VBN at_IN all_DT time_NN points_NNS and_CC were_VBD lower_JJR in_IN boys_NNS than_IN in_IN girls_NNS at_IN discharge_NN and_CC follow-up_NN ._SENT Spontaneous_JJ death_NN occurred_VBN in_IN cultured_JJ lymphocytes_NNS ,_, and_CC the_DT proportions_NNS of_IN freshly_RB isolated_VBN cells_NNS undergoing_VBG apoptosis_NN ,_, based_VBN on_IN annexin_NN V_NN and_CC propidium_NN iodide_NN staining_VBG ,_, were_VBD increased_VBN ._SENT Surface_NP Fas_NP was_VBD increased_VBN on_IN both_DT CD4_NP and_CC CD8_NP T_NN cells_NNS compared_VBN to_TO controls_NNS ,_, and_CC expression_NN was_VBD greater_JJR on_IN CD4_NP T_NN cells_NNS and_CC was_VBD inversely_RB correlated_VBN with_IN lymphocyte_NN viability_NN in_IN culture_NN at_IN study_NN entry_NN ._SENT Mitogen_NN stimulation_NN of_IN lymphocytes_NNS improved_VBN viability_NN ,_, but_CC inhibitors_NNS of_IN Fas_NP ,_, tumor_NN necrosis_NN factor_NN (TNF)-related_JJ apoptosis-inducing_NN ligand_NN ,_, and_CC TNF_NP did_VBD not_RB ._SENT Plasma_NN levels_NNS of_IN beta2_JJ microglobulin_NN and_CC soluble_JJ Fas_NP ,_, Fas_NP ligand_NN ,_, CD8_NP ,_, CD4_NP ,_, and_CC TNF_NP receptor_NN were_VBD increased_VBN ,_, and_CC soluble_JJ CD8_NN was_VBD higher_JJR in_IN boys_NNS than_IN in_IN girls_NNS ._SENT The_DT multiple_JJ effects_NNS of_IN measles_NN on_IN lymphocytes_NNS from_IN Zambian_JJ children_NNS include_VBP decreased_VBN numbers_NNS in_IN circulation_NN ,_, increased_VBN activation_NN ,_, and_CC increased_VBD susceptibility_NN to_TO cell_NN death_NN ,_, with_IN substantive_JJ differences_NNS in_IN the_DT magnitude_NN of_IN these_DT changes_NNS between_IN boys_NNS and_CC girls_NNS ._SENT Measles_NN causes_VBZ nearly_RB 1_CD million_CD deaths_NNS per_IN year_NN worldwide_RB ,_, with_IN the_DT heaviest_JJS burden_NN occurring_VBG in_IN sub-Saharan_JJ Africa_NP ._SENT The_DT high_JJ morbidity_NN and_CC mortality_NN associated_VBN with_IN measles_NN virus_NN (_( MV_NP )_) infection_NN is_VBZ due_JJ primarily_RB to_TO secondary_JJ infections_NNS ,_, particularly_RB of_IN the_DT respiratory_JJ and_CC gastrointestinal_JJ tracts_NNS ._SENT Increased_VBN susceptibility_NN to_TO other_JJ infectious_JJ diseases_NNS has_VBZ been_VBN linked_VBN to_TO the_DT immune_JJ suppression_NN associated_VBN with_IN this_DT infection_NN ._SENT Cell-mediated_JJ immunity_NN ,_, manifested_VBN by_IN decreased_VBN delayed-type_NN hypersensitivity_NN responses_NNS to_TO skin_VB test_NN antigens_NNS and_CC decreased_VBD proliferation_NN of_IN lymphocytes_NNS after_IN stimulation_NN in_IN vitro_NN ,_, is_VBZ suppressed_VBN ,_, and_CC this_DT suppression_NN may_MD persist_VB for_IN several_JJ months_NNS after_IN recovery_NN ._SENT The_DT mechanism_NN of_IN MV-induced_JJ immune_JJ suppression_NN is_VBZ incompletely_RB understood_VBN ,_, and_CC few_JJ studies_NNS of_IN children_NNS in_IN developing_VBG countries_NNS ,_, where_WRB mortality_NN rates_NNS are_VBP highest_JJS ,_, have_VBP been_VBN done_VBN ._SENT Lymphocyte_NN activation_NN is_VBZ a_DT consistent_JJ feature_NN of_IN acute_JJ measles_NN in_IN North_NP and_CC South_NP American_NP children_NNS ,_, and_CC we_PP have_VBP proposed_VBN that_IN the_DT observed_JJ cytokine_NN "_`` shift_NN "_'' from_IN type_NN 1_CD cytokines_NNS early_JJ during_IN infection_NN to_TO type_NN 2_CD cytokines_NNS during_IN and_CC after_IN recovery_NN inhibits_VBZ development_NN of_IN effective_JJ type_NN 1_CD cytokine-mediated_JJ cell-mediated_JJ immunity_NN responses_NNS upon_IN subsequent_JJ exposure_NN to_TO new_JJ pathogens_NNS ._SENT In_IN addition_NN ,_, lymphocyte_NN apoptosis_NN ,_, often_RB associated_VBN with_IN immune_JJ activation_NN ,_, is_VBZ a_DT feature_NN of_IN acute_JJ infections_NNS with_IN other_JJ immunosuppressive_JJ murine_NN and_CC human_JJ viruses_NNS ,_, and_CC it_PP has_VBZ been_VBN hypothesized_VBN that_IN increased_VBN apoptosis_NN of_IN lymphocytes_NNS in_IN individuals_NNS with_IN acute_JJ measles_NN may_MD contribute_VB to_TO immune_JJ suppression_NN ._SENT To_TO better_RBR understand_VB these_DT processes_NNS in_IN African_JJ children_NNS ,_, we_PP have_VBP evaluated_VBN the_DT functional_JJ and_CC phenotypic_JJ changes_NNS that_WDT occur_VBP during_IN acute_JJ MV_NP infection_NN and_CC recovery_NN from_IN measles_NN in_IN children_NNS hospitalized_VBN with_IN measles_NN in_IN Lusaka_NP ,_, Zambia_NP ._SENT Study_NN population_NN ._SENT |_SYM The_DT children_NNS studied_VBN (_( n_NN =_SYM 274_CD ;_: mean_JJ age_NN ,_, 3.05_CD +-_NN 0.21_CD years_NNS ;_: median_JJ age_NN ,_, 1.4_CD years_NNS ;_: range_NN ,_, 2_CD months_NNS to_TO 14.3_CD years_NNS )_) were_VBD a_DT subgroup_NN of_IN children_NNS enrolled_VBN in_IN a_DT study_NN of_IN the_DT clinical_JJ manifestations_NNS and_CC immune_JJ responses_NNS of_IN human_JJ immunodeficiency_NN virus_NN (HIV)-infected_JJ and_CC non-HIV-infected_JJ Zambian_JJ children_NNS hospitalized_VBN with_IN measles_NN between_IN January_NP 1998_CD and_CC August_NP 2000_CD ._SENT Children_NNS admitted_VBD to_TO the_DT infectious-disease_NN isolation_NN ward_NN at_IN the_DT University_NP Teaching_NP Hospital_NP (_( UTH_NN )_) in_IN Lusaka_NP ,_, Zambia_NP ,_, with_IN the_DT clinical_JJ diagnosis_NN of_IN measles_NN were_VBD prospectively_RB enrolled_VBN ._SENT Measles_NN was_VBD confirmed_VBN by_IN the_DT presence_NN of_IN immunoglobulin_NN M_NP (_( IgM_NP )_) antibody_NN against_IN MV_NP (_( Wampole_NP ,_, Cranbury_NP ,_, N.J._NP )_) ,_, and_CC children_NNS who_WP were_VBD HIV_NP infected_VBN ,_, as_RB determined_VBN by_IN the_DT presence_NN of_IN antibody_NN to_TO HIV_NP (_( Organon_NP Technika_NP ,_, Boxtel_NP ,_, The_DT Netherlands_NPS )_) and_CC reverse_VB transcription-PCR_NN detection_NN of_IN HIV_NP type_NN 1_CD RNA_NP (_( Amplicor_NP version_NN 1.5_CD ;_: Roche_NP Pharmaceuticals_NPS Inc._NP ,_, Branchburg_NP ,_, N.J._NP )_) were_VBD excluded_VBN ._SENT Children_NNS who_WP were_VBD moribund_JJ at_IN the_DT time_NN of_IN hospitalization_NN were_VBD not_RB enrolled_VBN in_IN the_DT study_NN ,_, although_IN many_JJ of_IN those_DT enrolled_VBN had_VBD severe_JJ or_CC complicated_JJ infections_NNS and_CC there_EX were_VBD four_CD deaths_NNS among_IN the_DT study_NN children_NNS ._SENT Samples_NNS from_IN all_DT children_NNS were_VBD not_RB included_VBN in_IN all_DT assays_NNS or_CC at_IN all_DT time_NN points_NNS due_JJ to_TO the_DT limited_JJ amounts_NNS of_IN blood_NN available_JJ ,_, difficulty_NN with_IN blood_NN drawing_NN ,_, or_CC parental_JJ withdrawal_NN from_IN the_DT study_NN ._SENT Not_RB all_DT children_NNS returned_VBN for_IN the_DT 1-month_JJ follow-up_NN visit_NN after_IN discharge_NN ,_, and_CC active_JJ tracing_NN was_VBD not_RB performed_VBN ._SENT Healthy_JJ control_NN children_NNS (_( n_NN =_SYM 98_CD ;_: mean_JJ age_NN ,_, 3.47_CD +-_NN 0.31_CD years_NNS ;_: median_JJ age_NN ,_, 1.75_CD years_NNS ;_: range_NN ,_, 6_CD months_NNS to_TO 9.4_CD years_NNS ;_: P_NN =_SYM 0.03_CD )_) were_VBD enrolled_VBN from_IN two_CD sources_NNS located_VBN within_IN 2.5_CD miles_NNS of_IN the_DT UTH_NN :_: the_DT clinic_NN for_IN well-child_JJ care_NN at_IN Chilenge_NP Health_NP Center_NP (_( <5_year 2_CD standard_JJ deviations_NNS below_IN the_DT norm_NN ,_, and_CC stunting_VBG was_VBD defined_VBN as_IN a_DT height-for-age_JJ >2_JJ standard_JJ deviations_NNS below_IN the_DT norm_NN (_( defined_VBN by_IN National_NP Center_NP for_IN Health_NP Statistics_NPS reference_NN values_NNS )_) ._SENT Nine_CD percent_NN of_IN the_DT children_NNS with_IN measles_NN and_CC 2.2_CD %_NN of_IN the_DT control_NN children_NNS were_VBD wasted_VBN (_( P_NN <_SYM 0.05_CD )_) ,_, and_CC 48.6_CD %_NN of_IN the_DT children_NNS with_IN measles_NN and_CC 33.7_CD %_NN of_IN the_DT control_NN children_NNS were_VBD stunted_VBN (_( P_NN <_SYM 0.02_CD ;_: chi2_NN test_NN )_) Blood_NP collection_NN and_CC processing_NN ._SENT |_SYM Peripheral_NP blood_NN ,_, collected_VBN in_IN a_DT sterile_JJ tube_NN containing_VBG EDTA_NP ,_, was_VBD obtained_VBN at_IN study_NN entry_NN (_( mean_VB ,_, 3.6_CD +-_NN 0.1_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: range_NN ,_, 1_CD to_TO 10_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: n_NN =_SYM 252_CD )_) ,_, at_IN hospital_NN discharge_NN (_( mean_VB ,_, 6.5_CD +-_NN 0.18_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: range_NN ,_, 2_CD to_TO 17_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: n_NN =_SYM 185_CD )_) ,_, and_CC at_IN a_DT 1-month_JJ follow-up_NN visit_NN (_( mean_VB ,_, 37.6_CD +-_NN 0.5_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: range_NN ,_, 25_CD to_TO 61_CD days_NNS after_IN onset_NN of_IN rash_NN ;_: n_NN =_SYM 78_CD )_) ._SENT White_JJ blood_NN cell_NN counts_NNS were_VBD determined_VBN manually_RB ._SENT Differential_JJ counts_NNS were_VBD performed_VBN on_IN Wright-Giemsa-stained_JJ smears_NNS by_IN the_DT hematology_NN laboratory_NN at_IN the_DT UTH_NN ._SENT Mononuclear_JJ cells_NNS were_VBD separated_VBN by_IN Ficoll-Hypaque_NP (_( Pharmacia_NP ,_, Piscataway_NP ,_, N.J._NP )_) density_NN gradient_JJ centrifugation_NN ._SENT Plasma_NN was_VBD frozen_VBN in_IN aliquots_NNS at_IN -80C_NN ._SENT Lymphocyte_NN viability_NN studies_NNS ._SENT |_SYM Washed_NP fresh_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMCs_NP )_) were_VBD suspended_VBN at_IN a_DT concentration_NN of_IN 106/ml_NP in_IN RPMI_NP 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN ,_, 10_CD mM_NP HEPES_NP ,_, and_CC 10_CD mug_NN of_IN gentamicin/ml_NN ._SENT The_DT cells_NNS were_VBD cultured_VBN ,_, with_IN or_CC without_IN stimulation_NN with_IN phytohemagglutinin_NN (_( PHA_NP ;_: 5_CD mug/ml_NN ;_: Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ,_, in_IN 96-well_NN round-bottom_NN microtiter_NN plates_NNS at_IN a_DT volume_NN of_IN 200_CD mul/well_NN ._SENT For_IN some_DT studies_NNS ,_, cells_NNS were_VBD cultured_VBN with_IN the_DT following_VBG inhibitors_NNS of_IN apoptosis_NN :_: tumor_NN necrosis_NN factor_NN (TNF)-related_JJ apoptosis-inducing_NN ligand-Fc_NN IgG_NP chimera_NN (_( 20_CD ng/ml_NNS )_) ,_, Fas-Fc_NP IgG_NP chimera_NN (_( 10_CD ng/ml_NNS )_) ,_, TNF_NP receptor_NN II_NP (TNFRII)-Fc_NP IgG_NP chimera_NN (_( 20_CD ng/ml_NNS )_) (_( R&D_NP Systems_NP ,_, Minneapolis_NP ,_, Minn._NP )_) ,_, and_CC mouse_NN anti-human_NP Fas_NP ligand_NN (_( FasL_NP )_) monoclonal_NN antibody_NN (_( 1_CD mug/ml_NN ;_: PharMingen_NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ._SENT Cell_NN viability_NN was_VBD determined_VBN by_IN trypan_JJ blue_JJ exclusion_NN ._SENT All_DT studies_NNS were_VBD performed_VBN on_IN fresh_JJ samples_NNS at_IN the_DT Virology_NP Laboratory_NP in_IN Lusaka_NP ._SENT Flow_NN cytometry_NN ._SENT |_SYM All_DT analyses_NNS were_VBD performed_VBN with_IN fresh_JJ samples_NNS at_IN the_DT Virology_NP Laboratory_NP in_IN Lusaka_NP on_IN a_DT FACScan_NP flow_NN cytometer_NN using_VBG Cell_NP Quest_NP software_NN (_( Becton_NP Dickinson_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) ._SENT Directly_RB conjugated_VBN mouse_NN monoclonal_NN antibodies_NNS to_TO the_DT following_VBG human_JJ antigens_NNS were_VBD used_VBN :_: CD3-fluorescein_NN isothiocyanate_NN (_( FITC_NP )_) ,_, CD4-phycoerythrin_NP (_( PE_NP )_) ,_, CD8-PE_NP (_( Becton_NP Dickinson_NP )_) ,_, and_CC Fas-FITC_NP (_( Antigenix_NP America_NP ,_, Huntington_NP Station_NP ,_, N.Y._NP )_) ._SENT In_IN each_DT case_NN ,_, staining_VBG was_VBD compared_VBN with_IN that_DT of_IN the_DT appropriately_RB labeled_VBN isotype_NN control_NN antibody_NN ._SENT The_DT percentages_NNS of_IN CD4_NP and_CC CD8_NP T_NN cells_NNS were_VBD determined_VBN after_IN staining_VBG whole_JJ blood_NN ._SENT CD3+/CD4+_NP and_CC CD3+/CD8+_NP cells_NNS were_VBD enumerated_VBN with_IN lymphocyte_NN gates_NNS set_VBN on_IN the_DT basis_NN of_IN forward_JJ and_CC side_JJ scatter_NN information_NN adjusted_VBN to_TO exclude_VB monocytes_NNS based_VBN on_IN percent_NN CD3-/CD4+_NN cells_NNS ._SENT Fas_NP expression_NN was_VBD measured_VBN on_IN CD4+_NP and_CC CD8+_NP subsets_NNS using_VBG the_DT same_JJ gates_NNS ._SENT The_DT percentage_NN of_IN freshly_RB isolated_VBN mononuclear_JJ cells_NNS staining_VBG with_IN annexin_NN V_NN only_RB was_VBD determined_VBN after_IN simultaneous_JJ staining_VBG with_IN annexin_NP V-FITC_NP and_CC propidium_NN iodide_NN (_( PI_NP )_) (_( R&D_NP Systems_NPS )_) using_VBG a_DT wide_JJ gate_NN based_VBN on_IN forward_JJ and_CC side_JJ scatter_NN information_NN which_WDT included_VBD dead_JJ and_CC dying_VBG cells_NNS ._SENT The_DT percentage_NN of_IN annexin_JJ V-positive_JJ cells_NNS at_IN entry_NN among_IN subsets_NNS was_VBD assessed_VBN after_IN 18_CD h_NN of_IN culture_NN by_IN dual_JJ staining_VBG for_IN annexin_NP V_CD and_CC CD4_NP or_CC CD8_NP ._SENT Soluble_JJ factors_NNS in_IN plasma_NN ._SENT |_SYM The_DT levels_NNS of_IN gamma_NN interferon_NN (_( IFN-gamma_NP ;_: BD_NP PharMingen_NP )_) ,_, soluble_JJ CD8_NP (_( sCD8_NN )_) ,_, sCD4_NP (_( Endogen_NP ,_, Woburn_NP ,_, Mass._NP )_) ,_, sTNFRII_NP (_( R&D_NP Systems_NP )_) ,_, sFas_NNS ,_, and_CC sFasL_NP (_( Medical_NP Biological_NP Laboratories_NPS ,_, Nagoya_NP ,_, Japan_NP )_) in_IN plasma_NN were_VBD measured_VBN by_IN enzyme_NN immunoassay_NN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT beta2_JJ microglobulin_NN was_VBD measured_VBN by_IN radioimmunoassay_NP (_( Pharmacia_NP &_CC Upjohn_NP ,_, Uppsala_NP ,_, Sweden_NP )_) ._SENT Values_NNS below_IN the_DT limit_NN of_IN detection_NN were_VBD assigned_VBN values_NNS midway_JJ between_IN zero_CD and_CC the_DT lower_JJR limit_NN of_IN detection_NN for_IN the_DT purposes_NNS of_IN analysis_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Data_NP are_VBP presented_VBN as_IN means_NN +-_NN standard_JJ errors_NNS of_IN the_DT mean_NN unless_IN otherwise_RB indicated_VBN ._SENT All_DT analyses_NNS were_VBD performed_VBN using_VBG STATVIEW_NP or_CC STATA_NP software_NN (_( SAS_NP ,_, Cary_NP ,_, N.C._NP )_) ._SENT Mann-Whitney_NP U_NP ,_, Wilcoxon_NP signed-rank_NP ,_, and_CC Spearman_NP rank_JJ correlation_NN coefficient_NN tests_NNS were_VBD used_VBN as_IN appropriate_JJ ,_, with_IN the_DT level_NN of_IN significance_NN set_VBN at_IN a_DT P_NN value_NN of_IN 0.05_CD ._SENT No_DT corrections_NNS were_VBD made_VBN for_IN multiple_JJ comparisons_NNS ._SENT Lymphopenia_NP ._SENT |_SYM The_DT numbers_NNS and_CC types_NNS of_IN leukocytes_NNS in_IN the_DT peripheral_JJ blood_NN were_VBD measured_VBN at_IN study_NN entry_NN (_( usually_RB the_DT day_NN after_IN admission_NN to_TO the_DT hospital_NN )_) ,_, at_IN discharge_NN from_IN the_DT hospital_NN ,_, and_CC approximately_RB 1_CD month_NN after_IN discharge_NN ,_, and_CC the_DT values_NNS were_VBD compared_VBN to_TO those_DT of_IN healthy_JJ children_NNS ._SENT On_IN entry_NN ,_, total_JJ leukocyte_NN counts_NNS were_VBD not_RB different_JJ between_IN measles_NN patients_NNS (_( 8,400_CD +-_NN 287_CD cells/mul_NN )_) and_CC controls_NNS (_( 8,300_CD +-_NN 345_CD cells/mul_NN )_) ,_, but_CC they_PP were_VBD increased_VBN in_IN measles_NN patients_NNS by_IN the_DT time_NN of_IN discharge_NN (_( 10,579_CD +-_NN 425_CD cells/mul_NN ;_: P_NN <_SYM 0.0001_CD )_) and_CC at_IN follow-up_NN (_( 10,610_CD +-_NN 498_CD cells/mul_NN ;_: P_NN =_SYM 0.0005_CD )_) ._SENT Monocyte_NN counts_NNS were_VBD increased_VBN at_IN all_DT times_NNS in_IN measles_NN patients_NNS compared_VBN to_TO controls_NNS ._SENT Lymphocyte_NN counts_NNS were_VBD decreased_VBN for_IN measles_NN patients_NNS at_IN study_NN entry_NN (_( 3,681_CD +-_NN 164_CD cells/mul_NN )_) compared_VBN to_TO controls_NNS (_( 5,650_CD +-_NN 240_CD cells/mul_NN ;_: P_NN <_SYM 0.0001_CD )_) and_CC were_VBD lower_JJR in_IN girls_NNS than_IN in_IN boys_NNS ._SENT The_DT lymphocyte_NN counts_NNS rose_VBD to_TO 5,835_CD +-_NN 298_CD cells/mul_NN at_IN the_DT time_NN of_IN discharge_NN and_CC to_TO 6,362_CD +-_NN 359_CD cells/mul_NN (_( P_NN =_SYM 0.27_CD )_) at_IN follow-up_NN ._SENT The_DT lymphocyte_NN counts_VBZ in_IN the_DT four_CD children_NNS who_WP died_VBD (_( girls_NNS aged_VBN 6_CD ,_, 8_CD ,_, and_CC 34_CD months_NNS ;_: boy_NN aged_VBN 8_CD months_NNS )_) were_VBD 1,200_CD ,_, 2,196_CD ,_, 2,280_CD ,_, and_CC 2,500_CD cells/mul_NN ,_, all_RB in_IN the_DT lowest_JJS quartile_NN at_IN study_NN entry_NN (_( 306_CD to_TO 2,873_CD cells/mul_NN )_) for_IN children_NNS with_IN measles_NN ._SENT However_RB ,_, the_DT lymphocyte_NN count_NN on_IN entry_NN did_VBD not_RB predict_VB the_DT disease_NN severity_NN as_IN measured_VBN by_IN days_NNS of_IN hospitalization_NN (_( rs_NNS =_SYM 0.013_CD ;_: P_NN =_SYM 0.85_CD ;_: Spearman_NP rank_JJ correlation_NN test_NN )_) ._SENT As_RB in_IN control_NN children_NNS (_( rs_NNS =_SYM -0.549_CD ;_: P_NN <_SYM 0.0001_CD )_) ,_, younger_JJR children_NNS with_IN measles_NN tended_VBN to_TO have_VB higher_JJR lymphocyte_NN counts_NNS than_IN older_JJR children_NNS at_IN study_NN entry_NN (_( rs_NNS =_SYM -0.456_CD ;_: P_NN <_SYM 0.0001_CD )_) and_CC higher_JJR numbers_NNS of_IN CD4_NP T_NN cells_NNS (_( rs_NNS =_SYM -0.418_CD ;_: P_NN <_SYM 0.0001_CD ;_: Spearman_NP rank_JJ correlation_NN test_NN for_IN all_DT comparisons_NNS )_) ._SENT Lymphopenia_NP was_VBD not_RB prolonged_JJ in_IN children_NNS <1_JJ year_NN of_IN age_NN (_( 4,652_CD +-_NN 316_CD cells/mul_NN on_IN entry_NN [_SYM n_NN =_SYM 85_CD ;_: P_NN <_0.0001], 38.5C_NN (_( 2,782_CD +-_NN 261_CD cells/mul_NN )_) than_IN in_IN children_NNS with_IN temperatures_NNS of_IN <38.5C_NN (_( 3,766_CD +-_NN 131_CD cells/mul_NN ;_: P_NN =_SYM 0.007_CD ;_: Student_NP 's_POS t_NN test_NN )_) ._SENT The_DT lymphocyte_NN count_NN did_VBD not_RB correlate_VB with_IN plasma_NN IFN-gamma_NP levels_NNS on_IN entry_NN (_( rs_NNS =_SYM -0.16_CD ;_: P_NN =_SYM 0.549_CD ;_: n_NN =_SYM 15_CD ;_: Spearman_NP rank_JJ correlation_NN test_NN )_) ._SENT The_DT absolute_JJ numbers_NNS of_IN CD4_NP and_CC CD8_NP T_NN lymphocytes_NNS were_VBD determined_VBN by_IN flow_NN cytometry_NN ._SENT The_DT numbers_NNS of_IN both_DT CD4_NP T_NN cells_NNS (_( 1,013_CD +-_NN 67_CD cells/mul_NN )_) and_CC CD8_NP T_NN cells_NNS (_( 782_CD +-_NN 56_CD cells/mul_NN )_) were_VBD depressed_VBN at_IN study_NN entry_NN compared_VBN to_TO controls_NNS (_( CD4_NP ,_, 2,007_CD +-_NN 93_CD cells/mul_NN [_SYM P_NN <_SYM 0.0001_CD ]_SYM ;_: CD8_NP ,_, 1,347_CD +-_NN 73_CD cells/mul_NN [_SYM P_NN <_SYM 0.0001_CD ]_SYM )_) ._SENT CD4_JJ T-cell_NN counts_NNS remained_VBD depressed_VBN at_IN discharge_NN (_( 1,813_CD +-_NN 155_CD cells/mul_NN [_SYM P_NN =_SYM 0.022_CD ]_SYM )_) but_CC had_VBD returned_VBN to_TO normal_JJ (_( 2,117_CD +-_NN 157_CD cells/mul_NN )_) at_IN the_DT 1-month_JJ follow-up_NN visit_NN ._SENT These_DT changes_NNS in_IN CD4_NP and_CC CD8_NP T-cell_NN numbers_NNS led_VBD to_TO lower_VB CD4/CD8_NP ratios_NNS at_IN study_NN entry_NN (_( 1.492_CD +-_NN 0.1_CD ;_: P_NN =_SYM 0.0024_CD )_) ,_, hospital_NN discharge_NN (_( 1.243_CD +-_NN 0.07_CD ;_: P_NN <_SYM 0.0001_CD )_) ,_, and_CC follow-up_NN (_( 1.527_CD +-_NN 0.11_CD ;_: P_NN =_SYM 0.041_LS )_) compared_VBN to_TO controls_NNS (_( 1.679_CD +-_NN 0.072_CD )_) ._SENT Because_IN CD8_NP T_NN cells_NNS tended_VBD to_TO increase_VB more_RBR rapidly_RB in_IN boys_NNS than_IN in_IN girls_NNS ,_, the_DT CD4/CD8_NP ratios_NNS were_VBD significantly_RB different_JJ by_IN sex_NN at_IN discharge_NN and_CC at_IN follow-up_NN ._SENT Lymphocyte_NN viability_NN ._SENT |_SYM To_TO determine_VB whether_IN lymphocytes_NNS from_IN measles_NN patients_NNS were_VBD more_RBR likely_JJ to_TO undergo_VB spontaneous_JJ cell_NN death_NN in_IN culture_NN ,_, the_DT viability_NN of_IN fresh_JJ PBMCs_NNS cultured_VBN without_IN stimulation_NN for_IN 3_CD days_NNS was_VBD assessed_VBN ._SENT Fewer_JJR cells_NNS from_IN measles_NN patients_NNS at_IN study_NN entry_NN than_IN from_IN control_NN children_NNS were_VBD viable_JJ when_WRB assessed_VBD 1_CD ,_, 2_CD ,_, and_CC 3_CD days_NNS after_IN being_VBG placed_VBN in_IN culture_NN (_( P_NN <_SYM 0.0001_CD for_IN all_DT comparisons_NNS )_) ._SENT On_IN day_NN 3_CD ,_, viability_NN was_VBD 74.7_CD %_NN +-_NN 1.3_CD %_NN in_IN cultures_NNS of_IN cells_NNS from_IN measles_NN patients_NNS compared_VBN to_TO 85.2_CD %_NN +-_NN 0.9_CD %_NN in_IN cultures_NNS of_IN cells_NNS from_IN control_NN children_NNS ._SENT The_DT tendency_NN to_TO undergo_VB spontaneous_JJ cell_NN death_NN improved_VBN with_IN time_NN after_IN acute_JJ measles_NN ,_, but_CC differences_NNS from_IN controls_NNS persisted_VBN at_IN hospital_NN discharge_NN (_( day_NN 3_CD viability_NN ,_, 78.7_CD %_NN +-_NN 1.5_CD %_NN ;_: P_NN =_SYM 0.0007_CD )_) and_CC at_IN the_DT follow-up_NN evaluation_NN 1_CD month_NN later_RBR (_( day_NN 3_CD viability_NN ,_, 81.5_CD %_NN +-_NN 1_CD %_NN ;_: P_NN =_SYM 0.0122_CD )_) ._SENT To_TO determine_VB whether_IN stimulation_NN of_IN lymphocytes_NNS in_IN vitro_NN would_MD alter_VB this_DT pattern_NN of_IN cell_NN death_NN ,_, the_DT viabilities_NNS of_IN cells_NNS cultured_VBN in_IN the_DT presence_NN of_IN PHA_NP were_VBD assessed_VBN ._SENT Cells_NNS from_IN children_NNS with_IN measles_NN had_VBD lower_JJR day_NN 3_CD viability_NN (_( 79.1_CD %_NN +-_NN 1.2_CD %_NN )_) at_IN study_NN entry_NN than_IN cells_NNS obtained_VBN from_IN control_NN children_NNS (_( 85_CD %_NN +-_NN 0.7_CD %_NN ;_: P_NN =_SYM 0.0001_CD )_) ._SENT However_RB ,_, at_IN later_JJR times_NNS during_IN recovery_NN there_EX were_VBD no_DT differences_NNS in_IN the_DT viabilities_NNS of_IN PHA-stimulated_JJ cells_NNS obtained_VBN from_IN children_NNS with_IN measles_NN and_CC those_DT obtained_VBN from_IN control_NN children_NNS ._SENT Surface_NN binding_NN of_IN annexin_NP V._NP |_SYM To_TO determine_VB whether_IN lymphocyte_NN death_NN was_VBD apoptotic_JJ and_CC whether_IN cells_NNS were_VBD primed_VBN for_IN apoptosis_NN in_IN vivo_RB ,_, PBMCs_NNS from_IN patients_NNS with_IN measles_NN were_VBD stained_VBN simultaneously_RB with_IN annexin_NP V_CD and_CC PI_NP ._SENT Annexin_NN V_CD binds_NNS phosphatidyl_JJ serine_NN residues_NNS exposed_VBN on_IN the_DT surfaces_NNS of_IN apoptotic_JJ and_CC necrotic_JJ cells_NNS ,_, while_IN PI_NP enters_VBZ only_RB necrotic_JJ cells_NNS ._SENT The_DT percentage_NN of_IN annexin_NP V+/PI-_NP cells_NNS was_VBD increased_VBN in_IN cells_NNS isolated_VBN from_IN measles_NN patients_NNS at_IN the_DT time_NN of_IN study_NN entry_NN (_( 28.7_CD %_NN +-_NN 2.2_CD %_NN )_) and_CC at_IN hospital_NN discharge_NN (_( 30.8_CD %_NN +-_NN 3.1_CD %_NN )_) compared_VBN to_TO cells_NNS obtained_VBN from_IN control_NN children_NNS (_( 22.2_CD %_NN +-_NN 2.2_CD %_NN ;_: P_NN =_SYM 0.0289_CD and_CC P_NN =_SYM 0.0134_CD ,_, respectively_RB )_) ._SENT Both_DT CD4_NP and_CC CD8_NP T_NN cells_NNS from_IN measles_NN patients_NNS at_IN the_DT time_NN of_IN study_NN entry_NN bound_VBN annexin_NP V_CD ,_, with_IN a_DT larger_JJR proportion_NN of_IN annexin_NP V-positive_NP CD8_NP T_NN cells_NNS (_( 17.7_CD %_NN +-_NN 1.6_CD %_NN )_) than_IN CD4_NP T_NN cells_NNS (_( 8.7_CD %_NN +-_NN 1.4_CD %_NN ;_: P_NN =_SYM 0.0007_CD )_) after_IN overnight_JJ culture_NN ._SENT Surface_NN expression_NN of_IN Fas_NP ._SENT |_SYM Surface_NP expression_NN of_IN Fas_NP (_( CD95_NP )_) ,_, a_DT member_NN of_IN the_DT TNFR_NP family_NN ,_, is_VBZ often_RB upregulated_JJ during_IN T-cell_NN activation_NN and_CC can_MD render_VB lymphocytes_NNS susceptible_JJ to_TO apoptosis_NN upon_IN interaction_NN with_IN cells_NNS expressing_VBG FasL_NP ._SENT There_EX was_VBD a_DT marked_JJ increase_NN in_IN the_DT percentage_NN of_IN CD4_NP T_NN cells_NNS expressing_VBG Fas_NP at_IN the_DT time_NN of_IN study_NN entry_NN (_( 25.9_CD %_NN +-_NN 3_CD %_NN )_) in_IN measles_NN patients_NNS compared_VBN to_TO control_VB children_NNS (_( 1.1_CD %_NN +-_NN 0.16_CD %_NN ;_: P_NN <_SYM 0.0001_CD )_) ,_, and_CC this_DT remained_VBD elevated_JJ at_IN discharge_NN (_( 22.5_CD %_NN +-_NN 3.4_CD %_NN ;_: P_NN <_SYM 0.0001_CD )_) and_CC 1_CD month_NN later_RBR (_( 8.2_CD %_NN +-_NN 2.3_CD %_NN ;_: P_NN =_SYM 0.0012_CD )_) ._SENT The_DT percentage_NN of_IN CD4_NP T_NN cells_NNS expressing_VBG Fas_NP at_IN study_NN entry_NN was_VBD inversely_RB correlated_VBN with_IN the_DT viabilities_NNS of_IN cultured_JJ PBMCs_NNS on_IN days_NNS 1_CD (_( rs_NN =_SYM -0.752_CD ;_: P_NN =_SYM 0.0067_CD )_) and_CC (_( rs_NNS =_SYM -0.598_CD ;_: P_NN =_SYM 0.0384_CD ;_: Spearman_NP rank_JJ correlation_NN test_NN )_) ._SENT There_EX was_VBD no_DT significant_JJ correlation_NN of_IN viability_NN with_IN Fas_NP expression_NN on_IN CD4_NP T_NN cells_NNS at_IN discharge_NN or_CC follow-up_NN (_( data_NNS not_RB shown_VBN )_) ._SENT A_DT smaller_JJR percentage_NN of_IN CD8_NP T_NN cells_NNS expressed_VBD Fas_NP ._SENT This_DT percentage_NN was_VBD elevated_VBN in_IN measles_NN patients_NNS at_IN the_DT time_NN of_IN study_NN entry_NN (_( 11.8_CD %_NN +-_NN 1.9_CD %_NN )_) compared_VBN to_TO control_VB children_NNS (_( 0.8_CD %_NN +-_NN 0.3_CD %_NN ;_: P_NN <_SYM 0.0001_CD )_) and_CC at_IN the_DT time_NN of_IN discharge_NN (_( 11.5_CD %_NN +-_NN 4.4_CD %_NN ;_: P_NN =_SYM 0.0004_CD )_) ,_, but_CC it_PP had_VBD returned_VBN nearly_RB to_TO normal_JJ (_( 1.95_CD %_NN +-_NN 0.6_CD %_NN ;_: P_NN =_SYM 0.0358_CD )_) by_IN the_DT 1-month_JJ follow-up_NN visit_NN ._SENT There_EX was_VBD no_DT correlation_NN of_IN lymphocyte_NN viability_NN in_IN culture_NN with_IN Fas_NP expression_NN on_IN CD8_NP T_NN cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Levels_NNS of_IN soluble_JJ cell_NN surface_NN proteins_NNS in_IN plasma_NN ._SENT |_SYM Soluble_JJ forms_NNS of_IN Fas_NP are_VBP produced_VBN by_IN activated_VBN PBMCs_NNS and_CC inhibit_VB Fas-induced_JJ cell_NN death_NN ._SENT Plasma_NN sFas_NNS levels_NNS were_VBD elevated_JJ (_( 1,910_CD +-_NN 132_CD ng/ml_NNS )_) in_IN measles_NN patients_NNS at_IN the_DT time_NN of_IN hospital_NN discharge_NN compared_VBN to_TO control_VB levels_NNS (_( 1,342_CD +-_NN 481_CD ;_: P_NN =_SYM 0.0006_CD )_) but_CC did_VBD not_RB differ_VB significantly_RB from_IN that_IN of_IN controls_NNS at_IN entry_NN (_( 1,463_CD +-_NN 124_CD )_) or_CC at_IN 1-month_JJ follow-up_NN (_( 1,491_CD +-_NN 115_CD )_) ._SENT sFasL_NN is_VBZ produced_VBN by_IN proteolytic_JJ cleavage_NN of_IN FasL_NP from_IN the_DT surfaces_NNS of_IN activated_VBN FasL-expressing_NP T_NN cells_NNS ._SENT sFasL_NN is_VBZ postulated_VBN to_TO suppress_VB Fas-mediated_JJ death_NN signals_NNS by_IN competitive_JJ binding_NN to_TO Fas_NP without_IN inducing_VBG apoptosis_NN ._SENT Children_NNS with_IN measles_NN had_VBD normal_JJ levels_NNS of_IN sFasL_NN in_IN their_PP$ plasma_NN at_IN study_NN entry_NN (_( 379_CD +-_NN 36_CD ng/ml_NNS )_) ._SENT These_DT levels_NNS rose_VBD by_IN hospital_NN discharge_NN (_( 432_CD +-_NN 42_CD ;_: P_NN =_SYM 0.0776_CD )_) and_CC were_VBD significantly_RB increased_VBN at_IN the_DT 1-month_JJ follow-up_NN visit_NN (_( 518_CD +-_NN 0.047_CD ng/ml_NNS ;_: P_NN =_SYM 0.0048_LS )_) compared_VBN to_TO the_DT levels_NNS in_IN the_DT plasma_NN of_IN control_NN children_NNS (_( 345_CD +-_NN 36_CD )_) ._SENT Soluble_JJ forms_NNS of_IN CD4_NP ,_, CD8_NP ,_, and_CC TNFRII_NP are_VBP shed_VBN from_IN the_DT surfaces_NNS of_IN activated_VBN lymphocytes_NNS ,_, and_CC levels_NNS of_IN beta2_JJ microglobulin_NN are_VBP increased_VBN as_IN a_DT consequence_NN of_IN immune_JJ activation_NN ._SENT Plasma_NN levels_NNS of_IN sCD8_NN ,_, sTNFRII_NP ,_, and_CC beta2_JJ microglobulin_NN were_VBD elevated_VBN at_IN entry_NN and_CC discharge_NN compared_VBN to_TO those_DT in_IN controls_NNS ,_, and_CC levels_NNS of_IN sTNFRII_NNS and_CC beta2_JJ microglobulin_NN remained_VBD elevated_JJ at_IN follow-up_NN ._SENT At_IN entry_NN ,_, sCD8_NN levels_NNS were_VBD higher_JJR in_IN boys_NNS (_( 1,056_CD +-_NN 599_CD U/ml_NN ;_: n_NN =_SYM 45_CD )_) than_IN in_IN girls_NNS (_( 761_CD +-_NN 468_CD ;_: n_NN =_SYM 31_CD ;_: P_NN =_SYM 0.0169_CD ;_: Mann-Whitney_NP U_NP test_NN )_) ,_, while_IN none_NN of_IN the_DT other_JJ molecules_NNS measured_VBD had_VBD levels_NNS that_WDT were_VBD significantly_RB different_JJ in_IN boys_NNS and_CC girls_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Effects_NNS of_IN inhibitors_NNS of_IN receptor-induced_JJ apoptosis_NN on_IN viability_NN of_IN cultured_JJ cells_NNS ._SENT |_SYM Several_JJ cell_NN surface_NN receptors_NNS in_IN addition_NN to_TO Fas_NP can_MD induce_VB cell_NN death_NN after_IN ligand_NN binding_NN ._SENT To_TO determine_VB if_IN blocking_VBG any_DT of_IN these_DT receptor-ligand_NN interactions_NNS would_MD protect_VB cultured_JJ lymphocytes_NNS from_IN measles_NN patients_NNS from_IN spontaneous_JJ cell_NN death_NN ,_, Fc_NP IgG_NP chimeras_NNS of_IN TNF-related_JJ apoptosis-inducing_NN ligand_NN ,_, Fas_NP ,_, and_CC TNFRII_NP and_CC a_DT FasL-blocking_NP antibody_NN were_VBD added_VBN to_TO cultured_JJ PBMCs_NNS ._SENT Viability_NN was_VBD determined_VBN after_IN 3_CD days_NNS in_IN culture_NN ._SENT None_NN of_IN these_DT inhibitors_NNS prevented_VBD the_DT spontaneous_JJ death_NN of_IN PBMCs_NNS obtained_VBN from_IN children_NNS with_IN measles_NN (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_NN of_IN measles_NN on_IN numbers_NNS of_IN leukocytes_NNS in_IN the_DT peripheral_JJ blood_NN ._SENT Effect_NN of_IN measles_NN on_IN numbers_NNS of_IN leukocytes_NNS in_IN the_DT peripheral_JJ blood_NN ._SENT The_DT mean_JJ absolute_JJ numbers_NNS of_IN leukocytes_NNS (_( A_NP )_) ,_, monocytes_NNS (_( B_NP )_) ,_, lymphocytes_NNS (_( C_NP )_) ,_, CD4_NP T_NN cells_NNS (_( D_NP )_) ,_, and_CC CD8_NP T_NN cells_NNS (_( E_NP )_) and_CC CD4/CD8_NP T-cell_NN ratios_NNS (_( F_NN )_) in_IN children_NNS with_IN measles_NN at_IN study_NN entry_NN ,_, hospital_NN discharge_NN ,_, and_CC 1-month_JJ follow-up_NN compared_VBN to_TO controls_NNS are_VBP shown_VBN ._SENT The_DT numbers_NNS of_IN CD4_NP and_CC CD8_NP T_NN cells_NNS were_VBD calculated_VBN using_VBG the_DT absolute_JJ lymphocyte_NN count_NN and_CC percentages_NNS of_IN CD3+_NP T_NN cells_NNS coexpressing_VBG CD4_NP or_CC CD8_NP ,_, as_RB measured_VBN by_IN flow_NN cytometry_NN ._SENT The_DT number_NN of_IN children_NNS in_IN each_DT group_NN is_VBZ indicated_VBN at_IN the_DT base_NN of_IN each_DT bar_NN ._SENT The_DT error_NN bars_NNS indicate_VBP standard_JJ errors_NNS of_IN the_DT mean_NN ._SENT ****_NN ,_, P_NN <_SYM 0.0001_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ;_: **_SYM ,_, P_NN <_SYM 0.01_CD ;_: *_SYM ,_, P_NN <_0.05 38_CD ._SENT Association_NN of_IN fever_NN with_IN numbers_NNS of_IN lymphocytes_NNS in_IN circulation_NN ;_: mean_VB lymphocyte_NN counts_NNS on_IN entry_NN for_IN children_NNS with_IN measles_NN stratified_VBN by_IN presence_NN or_CC absence_NN of_IN fever_NN of_IN >38.5C_NN ._SENT The_DT number_NN of_IN children_NNS in_IN each_DT group_NN is_VBZ indicated_VBN at_IN the_DT base_NN of_IN each_DT bar_NN ._SENT The_DT error_NN bars_NNS indicate_VBP standard_JJ errors_NNS of_IN the_DT mean_NN ._SENT **_SYM ,_, P_NN =_SYM 0.007_CD (_( Student_NP 's_POS t_NN test_NN )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Viability_NN of_IN mononuclear_JJ cells_NNS in_IN culture_NN ;_: mean_VB percent_NN viability_NN of_IN mononuclear_JJ cells_NNS isolated_VBN from_IN patients_NNS with_IN measles_NN compared_VBN to_TO controls_NNS after_IN culture_NN without_IN stimulation_NN (_( A_NP )_) and_CC with_IN PHA_NP stimulation_NN (_( B_NP )_) ._SENT Viability_NN of_IN mononuclear_JJ cells_NNS in_IN culture_NN ;_: mean_VB percent_NN viability_NN of_IN mononuclear_JJ cells_NNS isolated_VBN from_IN patients_NNS with_IN measles_NN compared_VBN to_TO controls_NNS after_IN culture_NN without_IN stimulation_NN (_( A_NP )_) and_CC with_IN PHA_NP stimulation_NN (_( B_NP )_) ._SENT Mononuclear_JJ cells_NNS were_VBD cultured_VBN with_IN or_CC without_IN 10_CD mug_NN of_IN PHA/ml_NP ._SENT Viability_NN was_VBD determined_VBN by_IN trypan_JJ blue_JJ exclusion_NN on_IN days_NNS 1_CD ,_, 2_CD ,_, and_CC 3_CD after_IN initiation_NN of_IN cultures_NNS ._SENT The_DT numbers_NNS of_IN unstimulated_JJ samples_NNS assessed_VBN were_VBD 68_CD to_TO 73_CD at_IN entry_NN ,_, 35_CD to_TO 47_CD at_IN discharge_NN ,_, 42_CD to_TO 46_CD at_IN follow-up_NN ,_, and_CC 54_CD to_TO 71_CD for_IN controls_NNS ._SENT The_DT numbers_NNS of_IN PHA-stimulated_JJ samples_NNS assessed_VBN were_VBD 53_CD to_TO 57_CD at_IN entry_NN ,_, 20_CD to_TO 29_CD at_IN discharge_NN ,_, 32_CD to_TO 36_CD at_IN follow-up_NN ,_, and_CC 54_CD to_TO 70_CD for_IN controls_NNS ._SENT The_DT error_NN bars_NNS indicate_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT ****_NN ,_, P_NN <_SYM 0.0001_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ;_: **_SYM ,_, P_NN <_SYM 0.01_CD ;_: *_SYM ,_, P_NN <_SYM 0.05_CD (_( Mann-Whitney_NP U_NP test_NN )_) ._SENT FIG._NN 4_CD ._SENT |_SYM Annexin_NP V_CD binding_NN to_TO lymphocytes_NNS ._SENT Annexin_NP V_CD binding_NN to_TO lymphocytes_NNS ._SENT Annexin_NP V_CD binding_NN to_TO the_DT cell_NN surfaces_VBZ of_IN PI-negative_NP PBMCs_NP (_( A_NP )_) and_CC of_IN CD4-PE-_NP or_CC CD8-PE-stained_NP T_NN lymphocytes_NNS obtained_VBN at_IN entry_NN and_CC cultured_VBN overnight_RB (_( B_NP )_) was_VBD measured_VBN by_IN flow_NN cytometry_NN using_VBG a_DT wide_JJ forward_NN and_CC side_NN scatter_NN gate_NN ._SENT The_DT number_NN of_IN samples_NNS in_IN each_DT group_NN is_VBZ indicated_VBN at_IN the_DT base_NN of_IN each_DT bar_NN ._SENT The_DT error_NN bars_NNS indicate_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT *_SYM ,_, P_NN <_SYM 0.05_CD (_( Mann-Whitney_NP U_NP test_NN )_) ;_: ***_NP ,_, P_NN <_SYM 0.001_CD (_( Wilcoxon_NP rank_NN test_NN )_) ._SENT FIG._NN 5_CD ._SENT |_SYM Fas_NP (_( CD95_NP )_) expression_NN on_IN the_DT surfaces_NNS of_IN lymphocytes_NNS during_IN measles_NN ._SENT Fas_NP (_( CD95_NP )_) expression_NN on_IN the_DT surfaces_NNS of_IN lymphocytes_NNS during_IN measles_NN ._SENT (_( A_NP and_CC B_NP )_) Mean_NP percentages_NNS of_IN CD4_NP (_( A_NP )_) and_CC CD8_NP (_( B_NP )_) T_NN cells_NNS from_IN measles_NN patients_NNS and_CC control_NN children_NNS with_IN surface_NN expression_NN of_IN Fas_NP ._SENT Fas_NP expression_NN was_VBD determined_VBN by_IN flow_NN cytometry_NN of_IN freshly_RB isolated_VBN CD4+_NP and_CC CD8+_NP lymphocytes_NNS gated_VBN by_IN forward_JJ and_CC side_JJ scatter_NN ._SENT The_DT number_NN of_IN samples_NNS in_IN each_DT group_NN is_VBZ indicated_VBN at_IN the_DT base_NN of_IN each_DT bar_NN ._SENT The_DT error_NN bars_NNS indicate_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT ****_NN ,_, P_NN <_SYM 0.0001_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ;_: **_SYM ,_, P_NN <_SYM 0.01_CD ;_: *_SYM ,_, P_NN <_SYM 0.05_CD (_( Mann-Whitney_NP U_NP test_NN )_) ._SENT (_( C_NP )_) Correlation_NN of_IN percent_NN Fas-positive_NP CD4_NP T_NN cells_NNS at_IN entry_NN with_IN lymphocyte_NN death_NN in_IN culture_NN ._SENT P_NN =_SYM 0.0067_CD (_( Spearman_NP rank_NN correlation_NN )_) ._SENT FIG._NN 6_CD ._SENT |_SYM Levels_NP of_IN soluble_JJ forms_NNS of_IN cell_NN surface_NN proteins_NNS ,_, sFas(A)_NN ,_, sFasL_NP (_( B_NP )_) ,_, sTNFRII_NP (_( C_NP )_) ,_, sCD4_NP (_( D_NP )_) ,_, and_CC sCD8_NP (_( E_NP )_) ,_, and_CC beta2_JJ microglobulin_NN (_( F_NN )_) in_IN plasma_NN of_IN measles_NN patients_NNS and_CC controls_NNS as_RB determined_VBN by_IN enzyme_NN or_CC radio_NN immunoassay_NN ._SENT Levels_NNS of_IN soluble_JJ forms_NNS of_IN cell_NN surface_NN proteins_NNS ,_, sFas(A)_NN ,_, sFasL_NP (_( B_NP )_) ,_, sTNFRII_NP (_( C_NP )_) ,_, sCD4_NP (_( D_NP )_) ,_, and_CC sCD8_NP (_( E_NP )_) ,_, and_CC beta2_JJ microglobulin_NN (_( F_NN )_) in_IN plasma_NN of_IN measles_NN patients_NNS and_CC controls_NNS as_RB determined_VBN by_IN enzyme_NN or_CC radio_NN immunoassay_NN ._SENT The_DT number_NN of_IN samples_NNS in_IN each_DT group_NN is_VBZ indicated_VBN at_IN the_DT base_NN of_IN each_DT bar_NN ._SENT The_DT error_NN bars_NNS indicate_VBP the_DT standard_JJ error_NN of_IN the_DT mean_NN ._SENT ****_NN ,_, P_NN <_SYM 0.0001_CD ;_: ***_NN ,_, P_NN <_SYM 0.001_CD ;_: **_SYM ,_, P_NN <_SYM 0.01_CD (_( Mann-Whitney_NP U_NP test_NN )_) ._SENT TABLE_NN 1_CD |_SYM Changes_NP in_IN numbers_NNS of_IN lymphocytes_NNS ,_, CD4_NP T_NN cells_NNS ,_, and_CC CD8_NP T_NN cells_NNS and_CC in_IN CD4/CD8_NP ratios_NNS in_IN boys_NNS and_CC girls_NNS with_IN measles_NN and_CC controls_NNS During_IN measles_NN ,_, the_DT rash_NN marks_VBZ the_DT onset_NN of_IN the_DT virus-specific_JJ immune_JJ response_NN ,_, the_DT initiation_NN of_IN virus_NN clearance_NN ,_, and_CC the_DT appearance_NN of_IN a_DT variety_NN of_IN immunologic_JJ abnormalities_NNS that_WDT often_RB persist_VBP for_IN weeks_NNS to_TO months_NNS after_IN recovery_NN ._SENT In_IN this_DT study_NN ,_, we_PP have_VBP evaluated_VBN the_DT functional_JJ and_CC phenotypic_JJ changes_NNS in_IN lymphocytes_NNS from_IN Zambian_JJ children_NNS with_IN measles_NN during_IN acute_JJ infection_NN and_CC after_IN recovery_NN from_IN infection_NN ._SENT Lymphopenia_NP occurred_VBD early_RB and_CC affected_VBD both_DT CD4_NP and_CC CD8_NP T_NN cells_NNS ._SENT Cells_NNS in_IN circulation_NN were_VBD activated_VBN and_CC susceptible_JJ to_TO apoptosis_NN as_IN indicated_VBN by_IN increased_VBN expression_NN of_IN Fas_NP ,_, binding_VBG of_IN annexin-V_NN ,_, and_CC spontaneous_JJ death_NN in_IN culture_NN ._SENT During_IN the_DT recovery_NN phase_NN ,_, lymphocyte_NN counts_NNS normalized_VBD rapidly_RB ,_, expression_NN of_IN Fas_NP decreased_VBD ,_, sFas_NNS and_CC sFasL_NN levels_NNS in_IN plasma_NN became_VBD elevated_JJ ,_, and_CC mitogen_NN stimulation_NN protected_VBD cells_NNS from_IN death_NN in_IN culture_NN ._SENT Lymphocyte_NN responses_NNS differed_VBD between_IN boys_NNS and_CC girls_NNS ._SENT In_IN boys_NNS ,_, lymphopenia_NNS was_VBD less_RBR marked_JJ ,_, CD8_JJ T_NN cells_NNS in_IN circulation_NN increased_VBN more_RBR rapidly_RB ,_, and_CC the_DT sCD8_JJ level_NN was_VBD higher_JJR than_IN in_IN girls_NNS ._SENT Therefore_RB ,_, in_IN children_NNS with_IN measles_NN ,_, T_NN lymphocytes_NNS undergo_VBP profound_JJ changes_NNS associated_VBN with_IN altered_JJ peripheral_JJ circulation_NN ,_, activation_NN ,_, apoptosis_NN ,_, and_CC susceptibility_NN to_TO death_NN in_IN culture_NN ._SENT The_DT differences_NNS in_IN responses_NNS between_IN boys_NNS and_CC girls_NNS may_MD be_VB linked_VBN to_TO sex-based_JJ differences_NNS in_IN measles_NN mortality_NN and_CC complications_NNS associated_VBN with_IN measles_NN immunization_NN ._SENT Lymphopenia_NP is_VBZ a_DT characteristic_NN of_IN many_JJ acute_JJ viral_JJ infections_NNS ,_, including_VBG measles_NN ._SENT Profound_JJ lymphopenia_NN has_VBZ previously_RB been_VBN associated_VBN with_IN severe_JJ measles_NN and_CC high_JJ mortality_NN in_IN African_JJ children_NNS ,_, and_CC the_DT four_CD children_NNS in_IN our_PP$ study_NN who_WP died_VBD during_IN hospitalization_NN had_VBD lymphocyte_NN counts_NNS in_IN the_DT lowest_JJS quartile_NN at_IN study_NN entry_NN ._SENT More_RBR profound_JJ decreases_NNS in_IN T-cell_NN counts_NNS during_IN acute_JJ measles_NN have_VBP also_RB been_VBN associated_VBN with_IN malnutrition_NN ,_, and_CC the_DT acutely_RB malnourished_JJ (_( wasted_VBN )_) children_NNS enrolled_VBN in_IN our_PP$ study_NN had_VBD lymphocyte_NN counts_VBZ lower_JJR than_IN those_DT of_IN children_NNS who_WP were_VBD not_RB wasted_VBN ._SENT Interestingly_RB ,_, stunted_JJ children_NNS had_VBD higher_JJR lymphocyte_NN counts_NNS ,_, but_CC the_DT reason_NN for_IN and_CC importance_NN of_IN this_DT observation_NN are_VBP unclear_JJ ._SENT In_IN our_PP$ study_NN ,_, profound_JJ lymphopenia_NN was_VBD also_RB associated_VBN with_IN female_JJ sex_NN ._SENT Lymphocyte_NN counts_NNS did_VBD not_RB predict_VB the_DT severity_NN of_IN disease_NN as_IN measured_VBN by_IN days_NNS of_IN hospitalization_NN ;_: however_RB ,_, this_DT parameter_NN does_VBZ not_RB accurately_RB measure_VB the_DT disease_NN severity_NN of_IN those_DT who_WP died_VBD during_IN hospitalization_NN ._SENT Furthermore_RB ,_, some_DT of_IN the_DT most_RBS severely_RB ill_JJ children_NNS were_VBD not_RB enrolled_VBN in_IN the_DT study_NN ,_, limiting_VBG our_PP$ ability_NN to_TO detect_VB these_DT relationships_NNS ._SENT Lymphopenia_NP was_VBD transient_JJ in_IN this_DT study_NN ,_, and_CC counts_NNS normalized_VBD quickly_RB as_IN the_DT fever_NN and_CC rash_NN resolved_VBN during_IN hospitalization_NN ._SENT Although_IN persistent_JJ lymphopenia_NN has_VBZ been_VBN associated_VBN with_IN ages_NNS of_IN <1_JJ year_NN in_IN Japanese_JJ children_NNS ,_, this_DT was_VBD not_RB seen_VBN in_IN Zambian_JJ infants_NNS ._SENT Genetic_JJ factors_NNS may_MD contribute_VB to_TO these_DT differences_NNS ._SENT In_IN addition_NN ,_, environmental_JJ factors_NNS ,_, such_JJ as_IN exposure_NN to_TO other_JJ infections_NNS ,_, nutritional_JJ status_NN ,_, and_CC prior_JJ immunization_NN ,_, may_MD also_RB play_VB as_RB yet_RB undefined_JJ roles_NNS ._SENT The_DT mechanism_NN by_IN which_WDT the_DT numbers_NNS of_IN lymphocytes_NNS in_IN circulation_NN are_VBP decreased_VBN during_IN the_DT acute_JJ phases_NNS of_IN viral_JJ diseases_NNS is_VBZ not_RB clear_JJ ._SENT Although_IN lymphopenia_NN has_VBZ been_VBN postulated_VBN to_TO be_VB due_JJ to_TO MV-induced_JJ death_NN of_IN T_NN cells_NNS ,_, MV_NP replicates_VBZ preferentially_RB in_IN macrophages_NNS ,_, and_CC circulating_VBG lymphocytes_NNS represent_VBP only_RB a_DT small_JJ proportion_NN of_IN the_DT total_JJ lymphocyte_NN population_NN ._SENT Therefore_RB ,_, alterations_NNS in_IN lymphocyte_NN trafficking_NN are_VBP more_RBR likely_JJ to_TO be_VB responsible_JJ for_IN profound_JJ ,_, transient_JJ changes_NNS in_IN the_DT numbers_NNS of_IN circulating_VBG lymphocytes_NNS ._SENT Increased_VBN exit_NN of_IN naive_JJ T_NN cells_NNS from_IN the_DT circulation_NN into_IN secondary_JJ lymphoid_JJ tissue_NN will_MD improve_VB the_DT chances_NNS that_IN lymphocytes_NNS capable_JJ of_IN recognizing_VBG viral_JJ antigens_NNS will_MD contact_VB appropriate_JJ antigen-presenting_NN cells_NNS ._SENT In_IN macaques_NNS with_IN measles_NN ,_, lymphocyte_NN counts_NNS decrease_VBP during_IN viremia_NN and_CC increase_NN after_IN the_DT onset_NN of_IN the_DT rash_NN ._SENT One_CD potential_JJ common_JJ mechanism_NN for_IN induction_NN of_IN altered_JJ trafficking_NN is_VBZ the_DT effect_NN of_IN increased_VBN temperature_NN ._SENT Fever_NN can_MD be_VB associated_VBN with_IN induction_NN of_IN inflammatory_JJ cytokines_NNS ,_, increased_VBD adhesion_NN of_IN lymphocytes_NNS to_TO lymph_NN node_NN vessels_NNS ,_, and_CC depletion_NN of_IN lymphocytes_NNS from_IN the_DT circulation_NN ._SENT Fever_NN is_VBZ a_DT universal_JJ feature_NN of_IN measles_NN ,_, typically_RB beginning_VBG 2_CD to_TO 3_CD days_NNS before_IN the_DT onset_NN of_IN the_DT rash_NN as_IN a_DT part_NN of_IN the_DT prodrome_NN ,_, a_DT time_NN when_WRB lymphocyte_NN counts_NNS are_VBP decreased_VBN ._SENT In_IN our_PP$ study_NN ,_, fever_NN at_IN the_DT time_NN of_IN study_NN entry_NN was_VBD specifically_RB associated_VBN with_IN low_JJ lymphocyte_NN counts_NNS ._SENT Lymphopenia_NN during_IN acute_JJ simian_JJ immunodeficiency_NN virus_NN infection_NN of_IN macaques_NNS has_VBZ been_VBN attributed_VBN to_TO alterations_NNS in_IN lymphocyte_NN trafficking_NN associated_VBN with_IN production_NN of_IN IFN-gamma_NP ._SENT Although_IN we_PP did_VBD not_RB find_VB a_DT correlation_NN between_IN plasma_NN IFN-gamma_NNS and_CC lymphocyte_NN counts_NNS in_IN measles_NN ,_, IFN-gamma_NP levels_NNS are_VBP highest_RBS early_JJ during_IN the_DT rash_NN and_CC could_MD contribute_VB to_TO altered_JJ trafficking_NN and_CC a_DT reduction_NN in_IN the_DT numbers_NNS of_IN circulating_VBG lymphocytes_NNS ._SENT Thus_RB ,_, lymphopenia_NN during_IN measles_NN is_VBZ likely_JJ to_TO involve_VB increased_VBN trafficking_NN of_IN peripheral_JJ blood_NN lymphocytes_NNS into_IN secondary_JJ lymphoid_JJ tissue_NN during_IN the_DT acute_JJ phase_NN of_IN the_DT immune_JJ response_NN to_TO infection_NN ._SENT The_DT increasing_VBG numbers_NNS of_IN lymphocytes_NNS in_IN circulation_NN during_IN recovery_NN probably_RB correspond_VB with_IN the_DT release_NN of_IN activated_VBN T_NN cells_NNS from_IN secondary_JJ lymphoid_JJ tissue_NN for_IN dissemination_NN to_TO sites_NNS of_IN virus_NN infection_NN Our_JJ previous_JJ studies_NNS have_VBP shown_VBN that_IN activated_VBN ,_, proliferating_VBG CD4_NP and_CC CD8_NP T_NN cells_NNS are_VBP found_VBN in_IN the_DT circulation_NN of_IN measles_NN patients_NNS after_IN the_DT onset_NN of_IN the_DT rash_NN ,_, and_CC the_DT present_JJ studies_NNS show_VBP that_IN Fas_NP ,_, another_DT marker_NN of_IN lymphocyte_NN activation_NN ,_, is_VBZ also_RB highest_JJS during_IN the_DT rash_NN ._SENT Decreases_NNS in_IN the_DT numbers_NNS of_IN both_DT CD4_NP and_CC CD8_NP T_NN cells_NNS contributed_VBD to_TO the_DT lymphopenia_NN ,_, but_CC CD4_NP T_NN cells_NNS were_VBD more_RBR depressed_VBN for_IN a_DT longer_JJR time_NN than_IN CD8_NP T_NN cells_NNS ,_, resulting_VBG in_IN decreased_VBN CD4/CD8_NP T-cell_NN ratios_NNS at_IN all_DT time_NN points_NNS ._SENT Late_RB in_IN infection_NN ,_, boys_NNS were_VBD the_DT major_JJ contributors_NNS to_TO the_DT overall_JJ CD4/CD8_NP T-cell_NN ratio_NN suppression_NN ._SENT A_DT previous_JJ study_NN of_IN measles_NN patients_NNS in_IN Senegal_NP also_RB noted_VBD the_DT tendency_NN for_IN girls_NNS to_TO have_VB higher_JJR percentages_NNS of_IN CD4_NP T_NN cells_NNS and_CC higher_JJR CD4/CD8_NP T-cell_NN ratios_NNS during_IN convalescence_NN ._SENT In_IN our_PP$ study_NN ,_, boys_NNS also_RB had_VBD higher_JJR levels_NNS of_IN sCD8_NN in_IN plasma_NN than_IN girls_NNS ,_, further_RBR suggesting_VBG greater_JJR stimulation_NN and_CC proliferation_NN of_IN CD8_NP T_NN cells_NNS in_IN response_NN to_TO infection_NN ._SENT There_EX is_VBZ intense_JJ interest_NN in_IN understanding_NN how_WRB girls_NNS and_CC boys_NNS differ_VBP in_IN their_PP$ responses_NNS to_TO measles_NN and_CC measles_NN immunization_NN ._SENT Studies_NNS from_IN Guinea-Bissau_NP and_CC South_NP Africa_NP have_VBP observed_VBN increased_VBN mortality_NN due_JJ to_TO measles_NN in_IN girls_NNS ,_, and_CC three_CD of_IN the_DT four_CD deaths_NNS in_IN our_PP$ study_NN were_VBD those_DT of_IN girls_NNS ,_, reflecting_VBG the_DT higher_JJR mortality_NN in_IN girls_NNS in_IN the_DT larger_JJR study_NN ._SENT Studies_NNS of_IN a_DT high-titer_NN measles_NN vaccine_NN showed_VBD long-term_JJ increased_VBN mortality_NN in_IN girls_NNS ,_, and_CC girls_NNS are_VBP more_RBR likely_JJ to_TO develop_VB fever_NN and_CC rash_NN after_IN routine_JJ measles-mumps-rubella_NN immunization_NN ._SENT Our_PP$ data_NNS showing_VBG more_JJR profound_JJ lymphopenia_NN and_CC less_JJR evidence_NN of_IN CD8_NP T-cell_NN activation_NN in_IN girls_NNS add_VBP to_TO the_DT accumulating_VBG evidence_NN for_IN an_DT important_JJ effect_NN of_IN sex_NN on_IN responses_NNS to_TO MV_NP and_CC suggest_VBP that_IN the_DT CD8_NP T-cell_NN response_NN may_MD be_VB an_DT important_JJ aspect_NN of_IN the_DT differences_NNS ._SENT The_DT vigor_NN and_CC timeliness_NN of_IN the_DT CD8_NP T-cell_NN response_NN is_VBZ likely_JJ to_TO be_VB important_JJ for_IN recovery_NN from_IN measles_NN ._SENT Other_JJ studies_NNS have_VBP shown_VBN that_IN circulating_VBG CD8_NP T_NN cells_NNS have_VBP cytotoxic_JJ activity_NN against_IN MV-infected_JJ cells_NNS ,_, and_CC CD8_NP T_NN cells_NNS are_VBP present_JJ at_IN sites_NNS of_IN MV_NP replication_NN and_CC are_VBP presumed_VBN to_TO play_VB an_DT important_JJ role_NN in_IN the_DT clearance_NN of_IN MV_NP from_IN infected_JJ tissues_NNS ._SENT Lymphocytes_NNS were_VBD susceptible_JJ to_TO cell_NN death_NN when_WRB placed_VBN in_IN culture_NN long_RB after_IN lymphocyte_NN numbers_NNS in_IN the_DT blood_NN had_VBD returned_VBN to_TO normal_JJ ,_, and_CC in_IN other_JJ studies_NNS this_DT abnormality_NN was_VBD present_JJ for_IN up_IN to_TO 6_CD months_NNS after_IN recovery_NN ._SENT The_DT propensity_NN for_IN lymphocytes_NNS to_TO die_VB in_IN culture_NN is_VBZ assumed_VBN to_TO reflect_VB the_DT in_IN vivo_JJ process_NN whereby_WRB virus-specific_JJ cells_NNS are_VBP eliminated_VBN after_IN virus_NN clearance_NN ._SENT The_DT death_NN of_IN activated_VBN T_NN cells_NNS can_MD be_VB induced_VBN by_IN at_IN least_JJS two_CD general_JJ pathways_NNS :_: an_DT active_JJ antigen-dependent_JJ pathway_NN that_WDT is_VBZ m_NN 